In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Oxford BioMedica (OXBDF – Research Report), with a price target of £14.50. The company’s shares closed last Thursday at $14.59, close to its 52-week high of $14.60.
According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 38.5% and a 57.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catabasis Pharmaceuticals, and Lineage Cell Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oxford BioMedica with a $20.00 average price target.
The company has a one-year high of $14.60 and a one-year low of $8.55. Currently, Oxford BioMedica has an average volume of 1,627.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. It operates through the Platform and Product segment. The Platform segment consists of the revenue generating bioprocessing and process development activities undertaken for third parties. The Product segment includes clinical and preclinical development of in vivo and ex vivo gene and cell therapy products which are owned by the group. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1996 and is headquartered in Oxford, the United Kingdom.